By Marie Rosenthal, MS
When able to make their own decisions, nearly all of the adolescent girls and young women who took part in a study accepted one of the two prevention products that were offered—the monthly dapivirine vaginal ring and emtricitabine-tenofovir disoproxil fumarate (FTC/TDF; Truvada, Gilead) as daily oral preexposure prophylaxis (PrEP).
In addition, the females were fairly adherent to their regimen, according to data presented at CROI 2022. Two-thirds of the females